Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists

SYBX - Synlogic Inc Stock Price, Fair Value and News

$1.31-0.11 (-7.75%)
Delayed
Max Portfolio Pct.
Check
Valuation
Check

Stock Quality:

GPSDBMFI
Max Portfolio Pct.
Check
Valuation
Check
GPSDBMFI

SYBX Price Action

Last 7 days

-20.6%

Last 30 days

-22.9%

Last 90 days

-10.3%

Trailing 12 Months

-6.4%

SYBX RSI Chart

MarAprMayJunJulAugSepOctNovDec0102030405060708090

SYBX Valuation

Market Cap

15.3M

Price/Earnings (Trailing)

-4.75

Price/Sales (Trailing)

7.12

EV/EBITDA

0.07

Price/Free Cashflow

-3.83

SYBX Price/Sales (Trailing)

202320242025024681012

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

SYBX Fundamentals

SYBX Revenue

Revenue (TTM)

2.8M

Rev. Growth (Yr)

-54.06%

Rev. Growth (Qtr)

-3.72%

2018202020222024500K1M1.5M2M2.5M3M

SYBX Earnings

Earnings (TTM)

-3.2M

Earnings Growth (Yr)

-1.9K%

Earnings Growth (Qtr)

-334.97%

201420162018202020222024-80M-60M-40M-20M0

SYBX Profitability

EBT Margin

-131.79%

Return on Equity

-31.25%

Return on Assets

-19.49%

Free Cashflow Yield

-26.13%

SYBX Investor Care

Shares Dilution (1Y)

0.02%

Diluted EPS (TTM)

-0.25

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
20172018201920202021202220232024500K1M1.5M2M2.5M3M
Net sales
YearQ1Q2Q3Q4
20250000
20243.3M3.1M2.8M0
20231.7M2.2M2.3M3.4M
20221.8M1.7M1.2M1.2M
2021854.8K1.2M1.5M1.8M
20202.5M2.5M2.4M545.0K
20192.5M2.6M1.1M2.2M
20182.7M830.0K2.5M2.5M
2017444.0K2.4M2.4M2.4M
2016000444.0K
Get all data in R, Python etc through our Historical Stock Data APIs

About Synlogic Inc

Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic and immunological diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase II clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine to treat solid tumors and lymphoma. It has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the research and pre-clinical development of a synthetic biotic medicine for the treatment of inflammatory bowel disease; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Cambridge, Massachusetts.
 CEO
 WEBSITEsynlogictx.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES72

Synlogic Inc Frequently Asked Questions

What is the ticker symbol for Synlogic Inc? What does SYBX stand for in stocks?

SYBX is the stock ticker symbol of Synlogic Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Synlogic Inc (SYBX)?

As of Wed Dec 03 2025, market cap of Synlogic Inc is 15.33 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SYBX stock?

You can check SYBX's fair value in chart for subscribers.

Is Synlogic Inc a good stock to buy?

The fair value guage provides a quick view whether SYBX is over valued or under valued. Whether Synlogic Inc is cheap or expensive depends on the assumptions which impact Synlogic Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SYBX.

What is Synlogic Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Dec 03 2025, SYBX's PE ratio (Price to Earnings) is -4.75 and Price to Sales (PS) ratio is 7.12. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SYBX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Synlogic Inc's stock?

In the past 10 years, Synlogic Inc has provided -0.294 (multiply by 100 for percentage) rate of return.